Citius Pharmaceuticals, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended June 30, 2022; filed August 11, 2022. The company is a development-stage specialty biopharmaceutical business with no product revenue to date.
Financial performance and liquidity
| Metric | Three months ended June 30, 2022 | Nine months ended June 30, 2022 | Comparable 2021 period |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Research and development expense | $4.89 million | $13.80 million | $2.20 million; $9.95 million |
| General and administrative expense | $3.02 million | $9.04 million | $3.41 million; $7.39 million |
| Net loss | $8.86 million | $25.65 million | $5.82 million; $18.09 million |
| Basic and diluted loss per share | $0.06 | $0.18 | $0.05; $0.20 |
| Cash used in operating activities | — | $22.03 million | $18.66 million |
Cash and cash equivalents were $48.04 million at June 30, 2022, down from $70.07 million at September 30, 2021. Working capital was approximately $46.4 million. Management estimated that available cash would fund operations through August 2023, with additional capital expected to be needed thereafter.
Total liabilities were $9.98 million, including $4.99 million in deferred tax liabilities and $0.72 million in operating lease liabilities. The filing reports no outstanding notes payable at period-end. With no revenue, gross margin is not applicable.
Material changes versus 2021
- Quarterly operating expenses rose to $8.92 million from $5.98 million, mainly as R&D increased by $2.68 million; quarterly net loss increased by $3.04 million.
- Nine-month operating expenses rose to $25.77 million from $18.33 million. Higher R&D, G&A, and stock-based compensation contributed to the $7.56 million increase in net loss.
- R&D spending included $6.51 million for I/ONTAK in the nine-month period and increased spending on the Mino-Lok and Halo-Lido programs. Lower ARDS expense partly offset these increases; 2021 included a $5.0 million NoveCite license fee.
- The 2021 comparison included a $1.45 million deemed dividend related to warrant extensions, affecting loss attributable to common stockholders and per-share results. There was no such charge in 2022.
- Cash declined during the 2022 nine-month period as operating activities used $22.03 million; financing activities provided no cash in that period. In 2021, equity offerings and warrant exercises had generated substantial financing proceeds.
Outlook, risks, and contingencies
- Management expected R&D expense to continue increasing as it advanced Mino-Lok and I/ONTAK Phase 3 programs, Halo-Lido, and work on ARDS and Mino-Wrap.
- The company reported April 2022 topline results from the I/ONTAK pivotal Phase 3 trial and anticipated filing a BLA in the second half of 2022. A Type B pre-BLA meeting with the FDA occurred July 12, 2022, after the quarter-end.
- The FDA issued a Study May Proceed letter for Halo-Lido’s Phase 2b trial; its first patient was enrolled in April 2022. Mino-Lok’s Phase 3 trial was being expanded to additional sites outside the United States.
- The company has incurred recurring losses and negative operating cash flows. Continued operations beyond the estimated August 2023 runway depend on raising capital, obtaining regulatory approvals, commercializing products, or securing strategic arrangements; none is assured.
- Licensing agreements carry potential milestone, royalty, and other payment obligations, including up to $51 million in NoveCite development and regulatory milestones and substantial I/ONTAK development and commercial milestones. These are contingent obligations, not current debt balances.
- Key risks include trial cost, timing and results; financing availability; regulatory approval; commercialization; and reliance on personnel, suppliers, and partners. The company reported no change in risk factors from its 2021 Form 10-K, no legal proceedings, and no off-balance-sheet arrangements.
Important facts for investors to verify
- Whether cash burn and R&D commitments remain consistent with the stated cash runway through August 2023 and the need for future financing.
- The status, timing, and FDA outcome of the I/ONTAK BLA, and subsequent milestones or costs under its licenses.
- Progress and trial results for Mino-Lok and Halo-Lido, including any changes to enrollment, timelines, or expected spending.
- Potential dilution: 146.13 million common shares were outstanding at June 30, 2022, with 40.01 million warrants outstanding and additional options.
- The amount and timing of contingent license payments, royalties, and other development commitments if programs advance or receive approval.